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Growing evidence indicates that reactive oxygen species (ROS) may play a key role in human heart failure (HF). Monoamine
oxidase (MAO) is emerging as a major ROS source in several cardiomyopathies. However, little is known about MAO activity in
human failing heart and its relationship with redox imbalance. Therefore, we measured MAO activity in the left (LV) and in the
right (RV) ventricle of human nonfailing (NF) and in end-stage ischemic (IHD) and nonischemic failing hearts.We found that both
MAO isoforms (MAO-A/B) significantly increased in terms of activity and expression levels only in IHD ventricles. Catalase and
aldehyde dehydrogenase-2 activities (ALDH-2), both implicated in MAO-catalyzed catecholamine catabolism, were significantly
elevated in the failing LV, whereas, in the RV, statistical significance was observed only for ALDH-2. Oxidative stress markers levels
were significantly increased only in the failing RV. Actin oxidation was significantly elevated in both failing ventricles and related to
MAO-A activity and to functional parameters.These data suggest a close association betweenMAO-A-dependent ROS generation,
actin oxidation, and ventricular dysfunction.This latter finding points to a possible pathogenic role ofMAO-A in humanmyocardial
failure supporting the idea that MAO-A could be a new therapeutic target in HF.
1. Introduction
Heart failure (HF) is a cardiovascular syndrome with high
morbidity and mortality characterized by complex patho-
physiology. The failing heart is the final step of different
cardiomyopathies. The altered myocardial phenotype and
metabolism lead to a progressive loss of left ventricular
efficiency. Among themechanisms involved inHF etiopatho-
genesis, a growing body of evidence suggests that reac-
tive oxygen species (ROS) and oxidative stress may play
a key role in both the initiation (myocardial remodelling)
and the progression towards overt HF [1]. A number of
intracellular ROS sources have been identified in animal
and human models of cardiac diseases, including NADPH
oxidase (NOX), xanthine oxidase, and nitric oxide synthase
activities. The mitochondrial respiratory chain is certainly
the best-characterized site for ROS generation in the cell.
Recently, an additional mitochondrial protein, monoamine
oxidase (MAO), is emerging as a major ROS source with
potential pathophysiological relevance [2, 3]. MAO is an
ubiquitously expressed FAD-dependent enzyme localized
at the outer mitochondrial membrane that exists in two
isoforms, MAO-A and B, with peculiar tissue distribution,
substrate selectivity, and inhibitor specificity [4]. MAO-A
substrates include noradrenaline (NE) and serotonin (5-
HT), while phenylethylamine is a specific substrate of MAO-
B. Oxidative deamination of MAO substrates that pro-
duces hydrogen peroxide and the corresponding aldehyde
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is selectively prevented by propargylamines (clorgyline and
deprenyl) [5]. Many studies have extensively highlighted the
role of MAO activity in the central nervous system [6–
8]; however, its relevance in other organs, including the
heart, has been investigated only recently. Increasing evi-
dence suggests that, in rodent cardiomyocytes, MAO activity
may contribute to NE- and 5-HT-induced hypertrophy, to
apoptosis, and to the stimulation of cell glucose uptake
by hydrogen peroxide generation [9–13]. These hydrogen
peroxide-mediated effects are particularly relevant since they
unmask a new receptor-independent roles of catecholamines
and 5-HT [14, 15], prompting the investigation on the possible
role ofMAO in cardiac diseases, includingHF. Indeed, recent
studies in animal models suggest that MAO-A/B activation
plays a crucial role in the progression from heart hypertrophy
towards failure, establishing a clear association between
MAO-induced ROS production, mitochondrial dysfunction,
and cardiac failure, leading to propose MAO as a new
promising therapeutic target in chronic diseases [3, 9, 15–
20]. Despite the clinical relevance of these findings and the
potential indication of MAO inhibitors for the treatment of
heart failure, little is known about MAO activity in human
failing heart and its relationship with redox imbalance. This
latter is a well-accepted, although not the sole, determinant
of the biochemical, metabolic, and functional derangement
leading to cardiac maladaptive response [1]. In the context
of humanHF, MAO-generated ROSmay be counterbalanced
by catalase (CAT), the antioxidant enzyme that catalyzes
the conversion of hydrogen peroxide into water and oxygen
[21], as well as by glutathione and thioredoxin-2 antioxidant
systems [21, 22]. Moreover, other cytotoxic products of MAO
activity and of lipid peroxidation such as aldehydes may
be scavenged by aldehyde dehydrogenase-2 (ALDH-2), the
mitochondrial isoform of ALDH. Aldehyde dehydrogenases
(ALDHs) are a superfamily of NAD(P)+-dependent enzymes
that oxidize aldehydes to their corresponding carboxylic
acids. In the myocardium, ALDH-2 plays an important
role in the removal of toxic aldehydes and protects the
heart against oxidative stress-injury [23]. Many studies have
reported that ALDH2 plays a protective role in models of
cardiovascular disease [23–28], whereas the lack or inhibition
of ALDH2 exacerbates the consequences of MAO-A [29] or
MAO-B [20] activation because of the accumulation of toxic
aldehydes. The latter findings have been recently obtained in
an experimental murine model of HF via pressure overload,
in which Kaludercic et al. [20] reported that aldehydes,
generated by amine catabolism via MAO-B, play a major role
in MAO-mediated mitochondrial dysfunction that, in turn,
leads to myocardial failure.
The present study was aimed at the following: (i) investi-
gating the activity of MAO isoforms (MAO-A and B) in the
left (LV) and in the right (RV) ventricle of nonfailing (NF)
and end-stage human failing hearts from ischemic (IHD) and
nonischemic (non-IHD) etiology; (ii) measuring the activity
of the enzymes implicated in MAO-catalyzed catecholamine
catabolism, namely, CAT and ALDH-2; (iii) assessing the
occurrence of oxidative stress markers, malondialdehyde
(MDA), and protein carbonyls; (iv) evaluating the oxidation
of sarcomeric myofibrillar proteins that may be critical for
Table 1: Clinical characteristics of the patients.
NF IHD Non-IHD
Total number 7 13 8
Sex (M/F) 5/2 12/1 7/1
Age (range) 52 (45–56) 55 (37–69) 45 (27–63)
LVEF (%) 27 ± 3.8 23 ± 2.5
PAP (mmHg) 38 ± 3.2 29 ± 5.4
PCWP (mmHg) 23 ± 3 21 ± 5.4
RAP (mmHg) 14 ± 4 11 ± 4.4
NYHA class III-IV III-IV
Diuretics 7 5
Digoxin 0 2
Antiarrhythmics 3 2
ACE-I 10 5
𝛽-blockers 7 5
Nitrates 4 0
Statins 2 0
ANF/rRNA 18S 1.03 ± 0.001 12.4 ± 1.05 12.3 ± 0.98
MCH-𝛼/rRNA 18S 1.30 ± 0.03 0.06 ± 0.01 0.04 ± 0.002
MCH-𝛽/rRNA 18S 1.35 ± 0.2 0.06 ± 0.02 0.54 ± 0.05
LVEF: left ventricular ejection fraction; ACE-I: angiotensin converting
enzyme inhibitors; PCWP: pulmonary capillary wedge pressure; PAP: pul-
monary artery pressure; RAP: right atrium pressure; HMGCoA inhibitors
(statins); ANF: atrial natriuretic factor; MHC: myosin heavy chain.
the development of contractile impairment; (v) establishing
a possible correlation between the activity of MAO-A, the
isoform indicated as a possible responsible contributing to
maladaptive heart remodelling and dysfunction, and func-
tional parameters that are indexes of LV and RV impairment
[30–32].
2. Materials and Methods
2.1. Tissue Origin and Preparation. The study conformed to
the Declaration of Helsinki and institutional ethical regula-
tions. Explanted failing hearts were obtained from patients
undergoing transplantation for end-stage HF secondary to
ischemic (IHD; 𝑛 = 13) and non-IHD (non-IHD; 𝑛 = 8)
diseases, including idiopathic dilated and valvular cardiomy-
opathy. Nonfailing (NF; 𝑛 = 7) donor hearts, unsuitable
for transplantation for technical reasons, (i.e., size incom-
patibility between donor and recipient) or for past medical
history of the donor (i.e., neoplasia), were used as controls.
Clinical characteristics of the three groups are shown in
Table 1. Immediately after explant, myocardial tissue sam-
ples were snap-frozen in liquid nitrogen-chilled isopentane
for protein determination, RNA analysis, and biochemical
assays. All tissues were stored at −80∘C. Sections stained
with hematoxylin-eosin and Masson Trichrome stain were
obtained from each sample for morphological examination
prior to each experiment. Histological slides were observed
under lightmicroscopy.Myocyte hypertrophywas a common
finding in all failing hearts, associated with variable degrees
of interstitial fibrosis, graded from mild (+1) to severe (+3)
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on a semiquantitative basis. According to the results of the
histologic examination, myocardial samples with minimal
amounts of fibrosis and devoid of inflammatory infiltrates
were selected for molecular and biochemical studies. In
addition, mRNA expression for atrial natriuretic factor, 𝛼-
and 𝛽-myosin heavy chain isoforms, molecular markers of
cardiac hypertrophy were evaluated quantitatively on both
NF and failing hearts by RT-PCR using the Platinum SYBR
Green qPCR Super Mix-UDG (Invitrogen).
2.2. MAO Activity. 100–130mg of tissue, from failing and
NF LV and RV, was minced in liquid nitrogen and then
homogenized by Ultra-Turrax in 0.1M phosphate buffer
(PBS) pH 7.8 containing 0.25M sucrose. Then, the samples
were centrifuged at 1000×g for 10min to remove cell debris
andnuclei. Protein contentwas evaluated by the BCAmethod
(Pierce Scientific Rockford, IL61101, USA).
MAO activity was radiochemically assayed as previously
described [33] using [14C]- 5-HT (1.0 𝜇Ci/mL; 100 𝜇M;Amer-
sham Biosciences, UK) or [14C]-benzylamine (1.0 𝜇Ci/mL;
100 𝜇M; Amersham Biosciences, UK) as substrates for
MAO-A and B, respectively. In particular, 40 𝜇L of tissue
homogenates was preincubated in 100 𝜇L of PBS, pH 7.8, at
37∘C for 30min in the absence or in the presence of theMAO
inhibitors pargyline (100 𝜇M; Sigma-Aldrich, St. Louis, MO,
USA) or semicarbazide (1.0mM; Sigma-Aldrich, St. Louis,
MO, USA) and of semicarbazide-sensitive amino oxidases,
respectively. Then, the labeled substrates were added to the
enzyme preparations for 30min at 37∘C. The reactions were
stopped by the addition of 20 𝜇L 3.0N HCl. The aldehyde
produced by enzyme reaction was extracted in ethyle acetate
(300 𝜇L) and the organic phase was separated by brief
spinning (1000×g for 5min); then an aliquot (150𝜇L) of the
sample was counted for radioactivity in a 𝛽-counter. MAO
activity was referred to as the radioactivity recovered in the
organic phase corrected for the percentage of nonmetabo-
lized substrate extracted in the organic phase. The results are
expressed as nmol/mg of proteins/30min.
2.3. Western Blot Determination of MAO Expression. Tissue
samples were homogenized in ice-cold PBS, pH 7.4, supple-
mentedwith 1.0mMPMSF, 10 𝜇Mleupeptin, 10 𝜇Maprotinin
1.0mM sodium orthovanadate, 1.0mM sodium fluoride,
and 1.0mM sodium pyrophosphate using a Dounce tissue
grinder, followed by two rounds of sonication (10 s each),
and clarified at 1000 ×g for 10min at 4∘C. The supernatant
was diluted in Laemmli sample buffer without bromophenol
blue and 2-mercaptoethanol, boiled for 3min, and cen-
trifuged at 12.000×g for 10min. Protein concentration in
the cleared lysate was determined using the BCA method;
equal protein amounts were separated on 12% SDS-PAGE
and transferred to an Immobilon-P membrane (Millipore
Corporation,MA, USA). After blocking with 5.0% (w/v) BSA
in 0.1% (v/v) PBS-Tween-20, the membrane was incubated
overnight at 4∘C with goat anti-MAO-B (1 : 1000, C-17) or
rabbit polyclonal anti-MAO-A (1 : 1000, H-70) antibodies.
Following 1.0 h incubation with donkey anti-goat (1 : 10 000,
sc-2020) or goat anti-rabbit (1 : 10 000, sc-2004) secondary
antibodies, the immunoreactive bands were detected by
the chemiluminescent Westar Supernova substrate (Cyan-
agen, Italy) and quantified by densitometric analysis using
a ChemiDoc system and the Quantity One software (Bio-
RAD Laboratories, Italy). Following membrane stripping,
mouse anti-𝛽-actin (1 : 1000, sc-81178) and goat anti-mouse
(1 : 10.000, sc-2062) were used as a reference for equal protein
loading. All primary and secondary antibodies were from
Santa Cruz Biotech (Santa Cruz, CA, USA).
2.4. CAT and ALDH-2 Activity Assay. CAT activity was mea-
sured spectrophotometrically in LV and RV homogenates
as previously described [34] and expressed as nmol/min/mg
protein.
ALDH-2 activity was assayed in the pellets obtained
after centrifugation at 15,000×g for 30min at 4∘C of cardiac
homogenates of LV and RV specimens; ALDH-2 activity was
measured spectrophotometrically following the reduction of
NAD+ at 340 nm after addition of benzaldehyde (400𝜇M;
Sigma-Aldrich, St. Louis, MO, USA) [35] and expressed as
nmol/min/mg protein.
2.5. Protein Carbonyls and MDA Assay. Carbonyl residues
were determined by the method of Correa-Salde and Albesa
[36]. Cardiac homogenates (50 𝜇L) were treated for 1 h with
150 𝜇L of 0.1% 2–4 dinitrophenylhydrazine (DNPH) (Sigma-
Aldrich, St. Louis, MO, USA) in 2.0M HCl and precipitated
with 10% trichloroacetic acid before centrifugation for 5min
at 10,000×g. The pellets were extracted three times with
500𝜇L of an ethanol/ethyl acetate mixture (1 : 1) and then
dissolved in 1.0mL of 6.0M guanidine-HCl (Sigma-Aldrich,
St. Louis, MO, USA) in 20mM PBS, pH 7.5. The solutions
were incubated at 37∘C for 30min and the insoluble debris
was removed by centrifugation. Sample absorbance was
measured at 370 nm.
The MDA content, as a marker of lipid peroxidation,
was evaluated with the specific “Bioxytech LPO-586” kit
(Oxis International Inc), according to the manufacturer
instructions.
2.6. Determination of Oxidized Proteins. The determination
of oxidized proteins was performed using the OxyBlot
Protein Oxidation Detection Kit (Millipore Corporation,
MA, USA) according to the manufacturer instructions, with
minor modifications. Tissue homogenates were obtained as
forwestern blot analysis but the lysis bufferwas supplemented
with 1.0% (v/v) 2-mercaptoethanol to prevent protein oxida-
tion after cell lysis. Following the 1000×g clarification step,
protein concentration was determined using the Bradford
reagent and 5 𝜇L of each sample containing 40 𝜇g of proteins
was denatured by adding 5.0 𝜇L of 12% SDS and by sample
incubation for 5min at 90∘C. Carbonyl groups introduced
into protein side chains following oxidation were derivatized
to 2,4-dinitrophenyl- (DNP-) hydrazone (DNPH) by reaction
withDNPH for 15min at RT.After neutralization, the samples
were centrifuged at 12,000×g for 2min, separated by 12%
SDS-PAGE, and transferred to an Immobilon-P membrane
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(Millipore Corporation, MA, USA). Western blot was per-
formed using a primary antibody specific for theDNPmoiety
of the proteins and a secondary goat anti-rabbit IgG, as
indicated in the kit protocol.The immunoreactive bandswere
detected as described for the western blot determination of
MAO. Antibody specificity for carbonylated proteins was
preliminarily verified by running samples incubated with the
providedDerivatization-Control solution, instead of with the
DNPH solution. The identification of carbonylated proteins
was performed by stripping and reprobing the membrane
with mouse anti-tropomyosin (CH1) (1 : 1000, sc-58868) or
anti-𝛼-actin (5C5) (1 : 1000, sc-58670) antibodies (Santa Cruz
Biotech, Santa Cruz, CA, USA).
2.7. Statistical Analysis. All values were expressed as mean
± SEM. Comparisons were performed using the Student 𝑡-
test and One-Way ANOVA followed by Dunnett’s post hoc
test when indicated. Correlation coefficient 𝑟 was obtained
using a linear (Pearson) correlation test (GraphPadPrism 5).
Results were considered to be significant at 𝑝 < 0.05.
3. Results
3.1. Total MAO (A + B) Activity in NF and Failing Ventricles.
TotalMAO activity, as a sum ofMAO-A andMAO-B activity,
was measured in LV and RV of NF and failing samples from
ischemic and nonischemic hearts. To exclude that age was a
possible cause of the increase of MAO activity we selected
hearts from patients with similar age. A significantly higher
activity in both ventricles was found only in IHD, whereas in
non-IHD failing hearts MAO activity was similar to that of
NF (Figure 1). These data suggest that the increase of MAO
activity may be related to disease etiology. On the basis of
these results further analyses were performed only in IHD
failing hearts.
3.2. Activity and Expression MAO Isoforms in NF and Failing
IHD Ventricles. To establish the contribution to total MAO
activity of either MAO isoform, we measured the activity
of MAO-A and MAO-B separately. In NF ventricles, both
MAO-A and B isoforms were present with a MAO-A/MAO-
B activity ratio of about 1 : 2-3-fold in both ventricles; in IHD
ventricles, MAO-A and B activities increased significantly as
compared to NF hearts (Figures 2(a) and 2(b)) with a similar
increase of the IHD/NF ratio of MAO isoform activity in
the respective ventricle (LV:MAO-A 8.40-fold; MAO-B: 7.33-
fold; RV:MAO-A5.92-fold;MAO-B4.73-fold).The enhanced
activities of both MAO isoforms in failing hearts could result
from overexpression. Therefore, we measured MAO-A and
MAO-B protein expressions by western blotting in the same
LVandRV samples inwhich their activitieswere evaluated. In
accordance with the measured activity, the MAO isoform/𝛽-
actin ratio determined by densitometric analysis showed
that both isoforms were significantly overexpressed in failing
ventricles as compared to the values found in NF hearts (NF
= 1) (LV: MAO-A 1.89-fold, 𝑝 < 0.01; MAO-B 1.56-fold,
𝑝 < 0.05; RV: MAO-A 1.48-fold, 𝑝 < 0.05; MAO-B 1.58,
𝑝 < 0.01), (Figures 2(c) and 2(d)).
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Figure 1: Total MAO activity in RV and LV of nonfailing (NF) and
failing hearts secondary to ischemic (IHD) and nonischemic (non-
IHD) diseases. Data are expressed as mean ± SEM. Comparison is
performed using ANOVA followed by Dunnett’s post hoc test. ∗∗𝑝 <
0.01 IHD RV versus NF RV; ∗𝑝 < 0.05 IHD LV versus NF LV. 𝑛 = 7
NF; 𝑛 = 13 IHD; 𝑛 = 8 non-IHD.
Even thoughwemeasured the activity andprotein expres-
sion of each MAO isoform in human failing hearts, we
were unable to distinguish the real contribution to HF of
either enzyme. The role of MAO-A in myocardial failure
is better described, although the contribution of MAO-B is
now emerging as important as MAO-A [20] in this scenario.
Therefore, for what the following results are concerned, we
considered only the contribution of the MAO-A isoform.
3.3. CAT and ALDH-2 Activities. With regard to the enzymes
involved in MAO catalysis, CAT activity was significantly
increased only in the failing LV of IHD hearts (𝑝 < 0.01)
(Figure 3(a)); in this ventricle CAT activity was also signifi-
cantly correlated to MAO-A activity (𝑟 = 0.91; 𝑝 < 0.029).
Differently from CAT, ALDH-2 activity was significantly
higher in both failing ventricles than in NF ones (LV versus
NF, 𝑝 < 0.05; RV versus NF, 𝑝 < 0.001) (Figure 3(b)),
whereas it was significantly related to MAO-A activity only
in LV (𝑟 = 0.92; 𝑝 < 0.028).
3.4. Oxidative Stress Markers. Once the activity and expres-
sion levels of MAO, CAT, and ALDH-2 in failing RV and
LV were assessed, we investigated oxidative stress markers
to determine whether the values found were associated with
different levels of oxidation products, including MDA and
protein carbonyls, typical markers of ROS-mediated attack to
lipids and proteins.Our results showed thatMDAandprotein
carbonyls were significantly increased only in failing RV as
compared to NF (MDA: IHD versus NF, 𝑝 < 0.01; protein
carbonyls: IHD versus NF, 𝑝 < 0.05) (Figures 4(a) and 4(b)),
whereas they were substantially unchanged in LV.
To assess whether total carbonylated proteins measured
in failing RV and LV included some myofibrillar proteins
critical for contractile performance of heart ventricles, we
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Figure 2:MAO isoform (MAO-A andB) activity (a, b) and expression (c, d) in RV and LVofNF and failing IHDventricles. Data are expressed
as mean ± SEM. ∗𝑝 < 0.05 failing versus NF. 𝑛 = 7 NF; 𝑛 = 13 IHD. Representative immunoblots (c) and densitometric quantification (d) of
ratio of MAO to 𝛽-actin protein expression expressed as fold increase of IHD with respect to NF = 1. ∗𝑝 < 0.05 failing versusNF; ∗∗𝑝 < 0.01
failing versus NF.
subjected derivatized proteins to SDS-PAGE coupled to anti-
DNP antibodies staining (Oxyblot). Figure 4(c) shows the
presence of a unique band, at 43 kDa, whose migration
corresponds to that of 𝛼-actin and whose identity was
confirmed by immunoblot with specific (anti-𝛼-actin) anti-
bodies (Figure 4(d)). No band was found at about 37 kDa,
corresponding to the Mr of tropomyosin. Interestingly, the
ratio between the densitometric value of actin stained with
anti-DNP antibodies and that of the corresponding band of
𝛼-actin, identified by immunoblot (actin oxidation index),
was significantly higher than that in NF in both failing RV
and LV (LV: 1.68-fold, 𝑝 < 0.05; RV: 1.58-fold, 𝑝 < 0.05),
in spite of a nonsignificant change in total carbonylated
protein content in failing LV. Finally, the comparison between
actin oxidation index observed in failing RV and LV and
MAO-A isoform activity showed a positive and significant
correlation (RV: 𝑟 = 0.68, 𝑝 = 0.001; LV: 𝑟 = 0.63; 𝑝 =
0.02).
3.5. Actin Oxidation Index andMAO-A Isoform Are Related to
FunctionalHeart Parameters. It is known that oxidative stress
affects heart physiology in normal and ischemic conditions.
Accordingly, we tested whether MAO-A isoform activity
and actin oxidation index were related to functional heart
parameters; among the latter, we considered the pulmonary
capillary wedge pressure (PCWP), used to diagnose the
severity of left ventricle failure and the pulmonary artery
pressure (PAP), an index of right ventricular failure and a
negative prognostic marker in HF. As shown in Figures 5(a)
and 5(b) all these parameters were positively and significantly
correlated in both ventricles, confirming that oxidative stress
affects the functional heart parameters.
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Figure 3: Catalase (a) and ALDH-2 activity (b) in RV and LV of NF and failing IHD ventricles. Data are expressed as mean ± SEM. ∗𝑝 < 0.05
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Figure 5: Actin oxidation index andMAO-A activity are correlated to functional parameters in RV and LV of failing IHD ventricles. LV actin
oxidation index is significantly correlated with LV MAO-A activity and pulmonary capillary wedge pressure (PCWP) as well as RV actin
oxidation index with RV MAO-A activity and pulmonary artery pressure (PAP). 𝑛 = 13 IHD.
4. Discussion
The present study reports for the first time that human end-
stage ischemic heart disease is associated with a significant
increase of MAO expression and activity responsible for
increased oxidative stress in failingRVandLV. In addition,we
found that the adaptive mechanisms needed to cope with the
increased oxidative stress are differently activated in failing
RV and LV, likely resulting in a greater risk of exposure to
oxidative stress damage for the RV than LV failure. Finally, a
significant correlation was observed between oxidative mod-
ification of actin, a key protein for heart contractility, MAO-
A activity, and the two heart functional parameters, PCWP
and PAP. This latter finding suggests a mechanistic link
among enzyme activation, protein chemical modifications,
and functional markers of relevance for cardiac impairment
in end-stage HF.
A deleterious role of the MAO-A/ROS pathway has been
reported in acute situations such as ischemia-reperfusion,
where pharmacological or genetic inactivation of MAO-A
prevents cardiac oxidative stress and cardiomyocyte death
[9, 12, 37].However, the importance of theMAO-A/H
2
O
2
axis
in chronic situations such as HF remains poorly understood.
Recently, Villeneuve et al. [18] observed that enhancedMAO-
A activity per se is sufficient to trigger deleterious effects
in the heart, particularly in cardiac diseases where MAO-A
upregulation was observed [15, 38]. Moreover, Kaludercic et
al. [20] showed that, under stress conditions, MAO-B activity
contributes to oxidative stress and structural and functional
derangements of the heart, establishing a direct relationship
between products of MAO activity, oxidative stress, and
mitochondrial dysfunction. All these studies were conducted
in animal or cellular models. Here we report that, in human
heart failure, the expression and activities of MAO isoforms
are strongly increased both in RV and in LV from failing
hearts in an etiology-dependent manner, in agreement with
previous studies [39, 40]. However, we could intriguingly
hypothesize that MAO-A and B expression/activity changes
are a response to a different accumulation of MAO substrates
includingNE and 5-HT [41, 42] or to the ischemia-dependent
release of humoral factors promoting MAO gene transcrip-
tion [38, 43]. Accordingly, MAO upregulation could well be
an adaptive mechanism yet becoming maladaptive on the
long-term.
We also found that two enzymes, CAT and ALDH-2,
involved in scavenging of MAO reaction products [3, 44],
were differently activated in LV and RV from ischemic
hearts. In fact, the activity of both enzymes was signifi-
cantly enhanced in LV, whereas, in RV samples, only the
increase of ALDH-2 was statistically significant. Whatever
the case, the increased scavenging capacity of CAT and
ALDH-2 in failing hearts may counteract the cytotoxic
effects of the products of MAO activity, notably in the LV.
In the failing RV, oxidative stress markers, such as MDA
and protein carbonylation, were significantly elevated. Thus,
the induction of antioxidant and detoxifying capacity in
the RV was not sufficient to compensate for the increased
oxidative stress, thus exposing the right heart chamber to
more severe oxidative damage. These findings agree with
our previous study [21] in which we observed that other
antioxidant enzyme systems (i.e., Mn-SOD, Gpx) were also
differently activated in RV versus LV, thus making the RV
more sensitive to oxidative stress. Therefore, despite a qual-
itative similarity of the biochemical mechanisms, generating
oxygen and carbonyl reactive species (i.e., MAO activity), the
elicited scavenging response was quantitatively different in
the RV and LV, suggesting that RV might be less equipped
than LV to counter oxidative/carbonyl stress. Accordingly,
Littlejohns et al. [45] showed a more prominent change of
protein expression profiles in the diseased RV compared
to LV. Lipid peroxidation and protein carbonylation are
likely to result from severe oxidative stress contributing to
dysfunction of heart contractility [46]. We found that the
level of total carbonylated proteinswas significantly increased
only in the RV. However, among sarcomeric myofibrillar
proteins, only actin (not tropomyosin) showed a significantly
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elevated oxidation index and, interestingly, this occurred also
in the failing LV. Previous studies demonstrated that actin
oxidation can cause formation of protein aggregates as a
result of sulfhydryl cross-linking or reaction of one protein
radical with an adjacent protein radical, resulting in cross-
linking and polymerization. Cross-linking of actin and other
contractile proteins could hinder the interactions of thick and
thin filaments thus interfering with excitation-contraction
coupling and contractile function [47]. Recently, Canton et
al. [46] observed that actin carbonylation appears to reflect
the oxidative degradation of myofibrillar proteins and that
the latter was correlated to contractile impairment in human
heart failure.
Interestingly, in our failing ventricles, the level of actin
oxidation was significantly related not only to MAO-A
activity, but also to PWCP in LV and to PAP in RV, respec-
tively.The correlation between enhanced oxidative stress and
PAP was previously observed also in the case of NADPH
oxidase, another source of ROS [48]. Our present data
suggest a close association between MAO-A-dependent ROS
generation, actin oxidation, and ventricular dysfunction,
supporting a general conclusion that increased oxidative
or/and carbonyl stress, combined with defective antioxidant
scavenging system as in the RV, is a hallmark of negative
outcome. Indeed, both increased PCWP and RV failures are
prognostic markers of progression to overt HF [30–32, 49,
50]. In this scenario, the overactivation of MAO-A in human
heart failure represents a novel finding that links oxidative
stress to a common alteration and prognostic marker of
HF, that is, increased levels of noradrenaline [41], a specific
MAO-A substrate. Therefore, the increase of noradrenaline
levels and MAO-A activity can represent a synergic, harmful
combination, as suggested by the correlation with clinical
markers of the disease.
In this study, we focused on MAO-A isoform and its
correlation with disease. However, the occurrence of abun-
dant protein level but, above all, the intense activity of
MAO-B suggest that MAO-B can also play a pathogenic
role in human cardiac diseases. In an experimental model of
chronic hemodynamic stress, Kaludercic et al. [20] showed
that increased MAO-B activity through ROS and aldehyde
production contributes to mitochondrial dysfunction that, in
turn, leads to cardiac structural and functional disarrange-
ment; on the contrary, lack or inhibition of MAO-B prevents
major cardiac adverse effects. In our opinion, the latter is
a very interesting finding and the first evidence that MAO-
B plays a role as significant as MAO-A in HF pathogenesis.
Accordingly, this new aspect deserves further investigation in
human failing hearts.
5. Limitations and Conclusions
Despite substantial progress in deciphering individual pro-
cesses involved in the initiation and gradual progression of
HF, our understanding of themolecularmechanisms ofHF in
humans is undermined by the multifactorial etiology of car-
diac dysfunction, by confounding comorbid conditions and
also by a lack of appropriate healthy controls. We are aware
that our study has significant limitations and needs future
extension. Nevertheless, our data provide new information
on the molecular/functional mechanisms responsible for the
progression towards end-stage heart failure and suggest a
new target for the development of more specific therapeutic
strategies for heart diseases. Previous evidence shows that
protein changes in heart failure from ischemic cardiomyopa-
thy involvemitochondria [40, 51, 52]. A recent study indicates
thatMAO is a key determinant of redox balance in the human
atrial myocardium and a biomarker for postoperative atrial
fibrillation, a common complication of heart surgery [53].
Even though the present results point to a possible pathogenic
role of MAO in humanmyocardial failure, in agreement with
other studies [53, 54], we cannot exclude the contribution
of other ROS sources. An intense cross-talk is likely to exist
among different ROS sources, in particular between MAO
and NOX; the latter has been convincingly suggested to play
a critical role in redox signalling and contractile dysfunction
of the heart, as previously reported by our and other studies
[1, 48, 52, 55]. It is conceivable that mitochondrial MAO is
part of a ROS circuitry that triggers or enhances intracellular
NOX activity. Unfortunately, to date, there is a lack of data on
the effect of specific NOX inhibitors; consequently, effective
clinical therapies targeting NOX remain elusive [1, 56]. On
the contrary, MAO inhibitors are available and already used
in clinic for treatment of neurodegenerative disorders such as
Parkinson’s and Alzheimer’s diseases [5, 57], and the available
information suggests that MAO inhibition is beneficial for
treatment of cardiovascular pathologies [58]. In this study we
propose these enzymes (and in particular MAO-A) as new
pharmacologic targets; moreover, the introduction of a new
generation of reversible MAO inhibitors lacking the so called
“cheese-effect” [3]makes attractive the idea of exploiting such
therapy for clinical use in congestive HF patients.
In conclusion, despite the strong support of a key role
of oxidative stress in the pathophysiology of heart failure
by experimental studies, the outcome of clinical trials using
different antioxidant approaches remains elusive. There is no
doubt that some drugs already in use for HF treatment may
act indirectly to ameliorate the excess of oxidative stress;
accordingly, identifying potential markers and targets for
novel HF therapies appears an important research objective.
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